Full Press Release Details
Alterity Therapeutics to Present
at the MST Access Hidden Gems in Life Sciences' Webinar
MELBOURNE, AUSTRALIA AND SAN
FRANCISCO, USA - 13 June 2024: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"),
a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David
Stamler, M.D., Chief Executive Officer will present a company overview at the MST Access Hidden Gems in Life Sciences' webinar
on Thursday, 13 June 2024 in Australia / Wednesday, 12 June 2024 in the United States.
Details are listed below and registration
AUSTRALIA PARTICIPANTS:
| Date: | Thursday, 13 June 2024 | |
| Time: | 1:30 p.m. AEST (Sydney/Melbourne) |
UNITED STATES PARTICIPANTS:
| Date: | Wednesday, 12 June 2024 | |
| Time: | 8:30 p.m. Pacific Time | |
| 11:30 p.m. Eastern Time |
To join the presentation, please click the webinar link
Investors will have the opportunity to ask questions during
the call, at the conclusion of the presentation.
A recording of the webinar will be made available on the Alterity
Therapeutics website after the event, which you can access here: www.alteritytherapeutics.com.
About Alterity Therapeutics Limited
Alterity Therapeutics
is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative
diseases. The Company's lead asset, ATH434, has the potential to treat various Parkinsonian disorders and is currently being
evaluated in two Phase 2 clinical trials in Multiple System Atrophy. Alterity also has a broad drug discovery platform generating
patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne,
Australia, and San Francisco, California, USA. For further information please visit the Company's website at
Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity
Therapeutics Limited.
Investor and Media Contacts: